SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Portola Pharmaceuticals, Inc. Initiates Phase 2 Study of PRT4445, Universal Antidote for Factor Xa Inhibitor Anticoagulants